Extrafine beclometasone dipropionate/formoterol fumarate Hietered-dose and dry-powder inhalers In asthma and chronic obstructive pulmonary disease: a profile of their use

摘要

Extrafine beclometasone dipropionate/formoterol 100/6 and 200/6 ug fixed-dose combination (FDC) is available in the EU as a pressurized metered-dose inhaler (Fostair, Foster, Formodual, Innovair, Inuvair, Inuxair, Combair) and a dry-powder inhaler (Fostair NEXThaler, Foster NEXThaler, Formodual NEXThaler, Innovair NEXThaler, Inuvair NEXThaler). It is an effective, convenient and well-tolerated option for maintenance, or maintenance and reliever therapy in patients with asthma, as well as for the symptomatic treatment of patients with severe chronic obstructive pulmonary disease (COPD). Extrafine beclometasone/formoterol is generally well tolerated, improves lung function and asthma control and reduces COPD exacerbations in these patients in clinical studies. It is generally more effective than beclometasone and formoterol monotherapies in clinical studies and generally provided better asthma control, reduced the use of rescue medication and improved health-related quality of life compared with large-particle FDCs in real-world studies.